

Application No. 10/717,378

Reply to Office Action

AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions, and listings, of claims in the application.

1. (Currently Amended) A method of treating a cellular proliferative disease, comprising administering to a mammalian host a pharmaceutical composition comprising:

(a) a therapeutically effective amount of liposomal entrapped irinotecan also comprising cardiolipin, ~~wherein the liposomal entrapped irinotecan demonstrates a irinotecan plasma concentration 200-fold higher than conventional irinotecan and~~

(b) a pharmaceutically acceptable expient, wherein at least a portion of irinotecan is complexed with cardiolipin.

2. (Original) The method of claim 1, wherein said mammalian host is a human.

3. (Canceled)

4. (Canceled)

5. (Canceled)

6. (Previously Presented) The method of claim 1, wherein said cardiolipin is selected from a group consisting of natural cardiolipin and synthetic cardiolipin.

7. (Original) The method of claim 1, wherein said liposome bears a negative charge.

8. (Original) The method of claim 1, wherein said liposome bears a positive charge.

9. (Canceled)

10. (Canceled)

11. (Currently Amended) A therapeutic composition comprising liposome entrapped irinotecan, wherein said liposome comprises a first liposome forming material comprising cardiolipin and a second liposome forming material and wherein the liposome

Application No. 10/717,378

Reply to Office Action

entrapped irinotecan demonstrates a irinotecan plasma concentration 200-fold higher than conventional irinotecan composition comprises about 1 wt.% to about 50 wt.% irinotecan, about 1 wt.% to about 50 wt.% cardiolipin, about 1 wt.% to about 95 wt.% phosphatidylcholine, and about 0.001 wt.% to about 5 wt.% α -tocopherol.

12. (Original) The composition of claim 11, wherein a portion of said cardiolipin is complexed with irinotecan.

13. (Previously Presented) The composition of claim 11, wherein said liposome entrapped irinotecan comprises vesicles having a size of about 5 μ m or less.

14. (Previously Presented) The composition of claim 11, wherein said liposome entrapped irinotecan comprises vesicles having a size of about 1 μ m or less.

15. (Previously Presented) The composition of claim 11, wherein said liposome entrapped irinotecan comprises vesicles having a size of about 0.5 μ m or less.

16. (Previously Presented) The composition of claim 11, wherein said liposome entrapped irinotecan comprises vesicles having a size of about 0.1 μ m or less.

17. (Previously Presented) The composition of claim 11, wherein said second liposome-forming material is a lipid selected from a group consisting of phosphatidylcholine, cholesterol, α -tocopherol, dipalmitoyl phosphatidylcholine and phosphatidylserine.

18. (Previously Presented) The composition of claim 11, wherein said cardiolipin is selected from a group consisting of natural cardiolipin and synthetic cardiolipin.

19. (Original) The composition of claim 11, wherein said liposome bears a negative charge.

20. (Original) The composition of claim 11, wherein said liposome bears a positive charge.

21. (Original) The composition of claim 11, wherein said liposome is neutral.

Application No. 10/717,378

Reply to Office Action

22. (Canceled)

23. (Original) A method for the treatment of mammalian cancer comprising administering a therapeutically effective amount of the composition of claim 11 to a subject in need thereof.

24-46. (Canceled)

47. (New) The method of claim 1, wherein the composition is administered at a dosage of about 0.5-3.0 mg irinotecan per kg body weight of the host.

48. (New) The method of claim 1, wherein the composition is administered at a dosage of about 1.0-3.0 mg irinotecan per kg body weight of the host.

49. (New) The method of claim 1 wherein the liposomal entrapped irinotecan comprises vesicles having a size of less than about 5 μm .

50. (New) The method of claim 1 wherein the liposomal entrapped irinotecan comprises vesicles having a size of about 1 μm or less.

51. (New) The method of claim 1 wherein the liposomal entrapped irinotecan comprises vesicles having a size of about 0.5 μm or less.

52. (New) The method of claim 1 wherein the liposomal entrapped irinotecan comprises vesicles having a size of about 0.1 μm or less.

53. (New) The method of claim 1 wherein the composition comprises about 1 wt.% to about 50 wt.% irinotecan, about 1 wt.% to about 50 wt.% cardiolipin, about 1 wt.% to about 95 wt.% phosphatidylcholine, and about 0.001 wt.% to about 5 wt.% α -tocopherol.